Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Evidence available on the effectiveness and costs of biological therapies for the initial treatment of metastatic colorectal cancer (mCRC) is scarce and contrasting. We conducted a population-based cohort investigation for assessing overall survival and costs associated with their use in a real-worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchi, Matteo, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Corrao, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226266/
https://www.ncbi.nlm.nih.gov/pubmed/32244478
http://dx.doi.org/10.3390/cancers12040839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226266/
https://www.ncbi.nlm.nih.gov/pubmed/32244478
http://dx.doi.org/10.3390/cancers12040839

Ejemplares similares